Alpha 2.0
Login Register
» Authors » Aleksandra Markovets

Aleksandra Markovets

Explore the profile of Aleksandra Markovets including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 1749
Followers 0
Related Specialties
Oncology
Biology
Pulmonary Medicine
Top 10 Co-Authors
J Carl Barrett
Juliann Chmielecki
Suresh S Ramalingam
Byoung Chul Cho
Ryan Hartmaier
Kenneth S Thress
Jhanelle E Gray
Paul D Smith
Margarita Majem
Yuri Rukazenkov
Published In
Nat Commun
J Thorac Oncol
J Clin Oncol
Clin Cancer Res
Nat Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
Gray J, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, et al.
J Thorac Oncol . 2024 Jul; 19(11):1525-1538. PMID: 39029876
Introduction: EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and...
2.
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Hobor S, Al Bakir M, Hiley C, Skrzypski M, Frankell A, Bakker B, et al.
Nat Commun . 2024 Jun; 15(1):4871. PMID: 38871738
The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here,...
3.
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations
Grazini U, Markovets A, Ireland L, ONeill D, Phillips B, Xu M, et al.
Clin Cancer Res . 2024 Apr; 30(18):4143-4154. PMID: 38630555
Purpose: Osimertinib is an EGFR tyrosine kinase inhibitor indicated for the treatment of EGFR-mutated (EGFRm)-driven lung adenocarcinomas. Osimertinib significantly improves progression-free survival in first-line-treated patients with EGFRm advanced non-small cell...
4.
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
Johnson M, Serra Traynor C, Vishwanathan K, Overend P, Hartmaier R, Markovets A, et al.
Clin Pharmacol Ther . 2023 Nov; 115(2):349-360. PMID: 38010260
This exploratory, post hoc analysis aimed to model circulating tumor DNA (ctDNA) dynamics and predict disease progression in patients with treatment-naïve locally advanced/metastatic epidermal growth factor receptor mutation (EGFRm)-positive non-small...
5.
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Gray J, Ahn M, Oxnard G, Shepherd F, Imamura F, Cheng Y, et al.
Clin Cancer Res . 2023 Jun; 29(17):3340-3351. PMID: 37379430
Purpose: Plasma circulating tumor DNA (ctDNA) analysis is used for genotyping advanced non-small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to predict outcomes. Patients And Methods:...
6.
Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
Chmielecki J, Gray J, Cheng Y, Ohe Y, Imamura F, Cho B, et al.
Nat Commun . 2023 Jun; 14(1):3179. PMID: 37263992
No abstract available.
7.
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
Chmielecki J, Gray J, Cheng Y, Ohe Y, Imamura F, Cho B, et al.
Nat Commun . 2023 Feb; 14(1):1070. PMID: 36849494
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved...
8.
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)
Suarez C, Larkin J, Patel P, Valderrama B, Rodriguez-Vida A, Glen H, et al.
J Clin Oncol . 2023 Feb; 41(14):2493-2502. PMID: 36809050
Purpose: Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) and programmed cell death...
9.
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
Criscione S, Martin M, Oien D, Gorthi A, Miragaia R, Zhang J, et al.
NPJ Precis Oncol . 2022 Dec; 6(1):95. PMID: 36575215
Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. While patients treated...
10.
Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
Lim S, Yang S, Lim S, Heo S, Daniel S, Markovets A, et al.
Ther Adv Med Oncol . 2022 Mar; 14:17588359221079125. PMID: 35251316
Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of -mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the...